S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.05%) $0.927
USD/NOK
(0.28%) $10.87
USD/GBP
(0.09%) $0.793
USD/RUB
(-0.35%) $92.25

Realtime updates for Urogen Pharma Ltd [URGN]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return 0.78%
SELL
50.00%
return -15.31%
Last Updated28 Mar 2024 @ 16:00

0.27% $ 15.00

SELL 64511 min ago

@ $19.19

Issued: 13 Feb 2024 @ 11:02


Return: -21.84%


Previous signal: Feb 12 - 15:11


Previous signal: Buy


Return: -0.20 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases...

Stats
Today's Volume 168 410
Average Volume 347 844
Market Cap 511.83M
EPS $0 ( 2024-03-21 )
Next earnings date ( $-0.930 ) 2024-05-09
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -4.23
ATR14 $0.0270 (0.18%)
Insider Trading
Date Person Action Amount type
2024-03-18 Schoenberg Mark Sell 12 000 Ordinary Shares
2024-01-31 Kim Dong Buy 3 333 Ordinary Shares
2022-03-25 Kim Dong Buy 20 000 Stock Option (right to buy)
2024-02-01 Smith Jason Drew Sell 3 328 Ordinary Shares
2024-02-01 Smith Jason Drew Sell 1 248 Ordinary Shares
INSIDER POWER
58.27
Last 96 transactions
Buy: 1 308 776 | Sell: 407 960

Volume Correlation

Long: 0.02 (neutral)
Short: -1.00 (very strong negative)
Signal:(44.192) Neutral

Urogen Pharma Ltd Correlation

10 Most Positive Correlations
SVAC0.916
GOODM0.907
TLGT0.891
MTSL0.871
NSTS0.866
TTWO0.86
LUNG0.851
PAIC0.851
RMNI0.845
RCM0.833
10 Most Negative Correlations
LWAC-0.955
SRAC-0.919
AMRB-0.902
LMRKN-0.889
NETE-0.881
KNSA-0.847
UTHR-0.847
RAVN-0.84
OFS-0.831
TECH-0.828

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Urogen Pharma Ltd Correlation - Currency/Commodity

The country flag -0.28
( neutral )
The country flag -0.07
( neutral )
The country flag 0.00
( neutral )
The country flag -0.68
( moderate negative )
The country flag 0.58
( weak )
The country flag 0.18
( neutral )

Urogen Pharma Ltd Financials

Annual 2023
Revenue: $82.71M
Gross Profit: $73.35M (88.68 %)
EPS: $-3.55
Q4 2023
Revenue: $23.53M
Gross Profit: $21.24M (90.28 %)
EPS: $-0.720
Q3 2023
Revenue: $20.85M
Gross Profit: $18.49M (88.65 %)
EPS: $-0.680
Q2 2023
Revenue: $21.14M
Gross Profit: $18.70M (88.44 %)
EPS: $-1.030

Financial Reports:

No articles found.

Urogen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators